HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
126:@0.078769:0.033217:0.109813:0.033217:0.109813:0.013052:0.078769:0.013052:0.010348:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
of current regimens and the benefit of early therapy in :@0.076190:0.084931:0.485115:0.084931:0.485115:0.069149:0.076190:0.069149:0.009903:0.004747:0.005020:0.009782:0.009192:0.004551:0.004551:0.009812:0.009223:0.005125:0.005020:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.005866:0.005035:0.010326:0.009223:0.010357:0.005035:0.005125:0.009223:0.009827:0.005020:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005020:0.009903:0.004747:0.005020:0.009827:0.010326:0.004551:0.003024:0.008104:0.005035:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.005020:0.003024:0.009223:0.004188
terms of morbidity and mortality with the reduced risk of :@0.076190:0.099040:0.485175:0.099040:0.485175:0.083257:0.076190:0.083257:0.005125:0.009827:0.004551:0.014182:0.005866:0.003886:0.009903:0.004747:0.003901:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.003901:0.010326:0.009223:0.010357:0.003901:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.003901:0.012564:0.003024:0.005125:0.009223:0.003901:0.005125:0.009223:0.009827:0.003886:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.003886:0.004551:0.003024:0.005866:0.007590:0.003901:0.009903:0.004747:0.004188
transmission.:@0.076190:0.113148:0.166557:0.113148:0.166557:0.097366:0.076190:0.097366:0.005125:0.004551:0.010326:0.009223:0.005866:0.014182:0.003024:0.005866:0.005866:0.003024:0.009903:0.009223:0.004188
5-8:@0.166558:0.107860:0.179185:0.107860:0.179185:0.098706:0.166558:0.098706:0.004858:0.002911:0.004858
The most recent south African ART guidelines are now :@0.090476:0.127272:0.485128:0.127272:0.485128:0.111489:0.090476:0.111489:0.006441:0.009223:0.009827:0.003870:0.014182:0.009903:0.005866:0.005125:0.003886:0.004551:0.009827:0.009782:0.009827:0.009223:0.005125:0.003870:0.007529:0.009903:0.009192:0.005125:0.009223:0.003870:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.009223:0.003870:0.011188:0.009177:0.006441:0.003870:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.003886:0.010326:0.004551:0.009827:0.003886:0.009223:0.009903:0.012564:0.004188
in line with the WHO guideline, which recommends ini-:@0.076189:0.141380:0.480940:0.141380:0.480940:0.125598:0.076189:0.125598:0.003024:0.009223:0.005216:0.003024:0.003024:0.009223:0.009827:0.005216:0.012564:0.003024:0.005125:0.009223:0.005201:0.005125:0.009223:0.009827:0.005201:0.014514:0.010326:0.013138:0.005216:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.004188:0.005201:0.012564:0.009223:0.003024:0.009782:0.009223:0.005201:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.005866:0.005201:0.003024:0.009223:0.003024:0.005020
tiating ART regardless of CD4 count. There are specific :@0.076189:0.155489:0.485113:0.155489:0.485113:0.139706:0.076189:0.139706:0.005125:0.003024:0.010326:0.005125:0.003024:0.009223:0.010175:0.005382:0.011188:0.009177:0.006441:0.005382:0.004551:0.009827:0.010175:0.010326:0.004551:0.010357:0.003024:0.009827:0.005866:0.005866:0.005382:0.009903:0.004747:0.005382:0.012292:0.011249:0.008376:0.005382:0.009782:0.009903:0.009192:0.009223:0.005125:0.004188:0.005367:0.006441:0.009223:0.009827:0.004551:0.009827:0.005367:0.010326:0.004551:0.009827:0.005382:0.005866:0.010311:0.009827:0.009782:0.003024:0.003681:0.003681:0.009782:0.004188
clinical scenarios in which ART should be deferred in pa-:@0.076189:0.169597:0.480925:0.169597:0.480925:0.153815:0.076189:0.153815:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.003644:0.005866:0.009782:0.009827:0.009223:0.010326:0.004551:0.003024:0.009903:0.005866:0.003629:0.003024:0.009223:0.003629:0.012564:0.009223:0.003024:0.009782:0.009223:0.003629:0.011188:0.009177:0.006426:0.003629:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003629:0.010311:0.009827:0.003629:0.010357:0.009827:0.004747:0.009827:0.004551:0.004551:0.009827:0.010357:0.003613:0.003024:0.009223:0.003629:0.010311:0.010326:0.005020
tients with HIV, due to the risks of toxicity and immune :@0.076189:0.183706:0.485128:0.183706:0.485128:0.167923:0.076189:0.167923:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005700:0.012564:0.003024:0.005125:0.009223:0.005715:0.010326:0.003417:0.010614:0.004188:0.005715:0.010357:0.009192:0.009827:0.005700:0.005125:0.009903:0.005700:0.005125:0.009223:0.009827:0.005700:0.004551:0.003024:0.005866:0.007590:0.005866:0.005715:0.009903:0.004747:0.005700:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.005715:0.010326:0.009223:0.010357:0.005715:0.003024:0.014182:0.014182:0.009192:0.009223:0.009827:0.004188
reconstitution inflammatory syndrome (IRIS).:@0.076189:0.197814:0.394822:0.197814:0.394822:0.182032:0.076189:0.182032:0.004551:0.009827:0.009782:0.009903:0.009223:0.005866:0.005125:0.003024:0.005125:0.009192:0.005125:0.003024:0.009903:0.009223:0.004188:0.003024:0.009223:0.003666:0.003666:0.010326:0.014182:0.014182:0.010326:0.005125:0.009903:0.004551:0.008104:0.004188:0.005866:0.008104:0.009223:0.010357:0.004551:0.009903:0.014182:0.009827:0.004188:0.005579:0.003417:0.009177:0.003417:0.007529:0.005579:0.004188
5-7:@0.394798:0.192540:0.407425:0.192540:0.407425:0.183387:0.394798:0.183387:0.004858:0.002911:0.004858
first-line therapy in an Art-naïve HiV-infected :@0.076190:0.229023:0.452486:0.229023:0.452486:0.210692:0.076190:0.210692:0.008063:0.004032:0.005376:0.007392:0.005040:0.007056:0.004032:0.004032:0.010079:0.010751:0.004704:0.005040:0.010079:0.010751:0.005376:0.011087:0.011087:0.009743:0.004704:0.004032:0.010079:0.004704:0.011087:0.010079:0.004704:0.012431:0.009743:0.007056:0.007056:0.010079:0.011087:0.004032:0.009407:0.010751:0.004704:0.011423:0.004704:0.011759:0.007056:0.004032:0.010079:0.004704:0.010751:0.010751:0.005040:0.010751:0.011087:0.004704
patient:@0.076190:0.244417:0.133307:0.244417:0.133307:0.226086:0.076190:0.226086:0.011087:0.011087:0.005040:0.004032:0.010751:0.010079:0.005040
All guidelines previously recommended  a NNRTI  and :@0.076190:0.260705:0.485130:0.260705:0.485130:0.244922:0.076190:0.244922:0.011188:0.003024:0.003024:0.008028:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.008028:0.010311:0.004551:0.009827:0.008376:0.003024:0.009903:0.009192:0.005866:0.003024:0.008104:0.008028:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.003825:0.010326:0.008028:0.011188:0.011188:0.009177:0.006441:0.003417:0.004188:0.003825:0.010326:0.009223:0.010357:0.004188
two NRTIs as first-line ART therapy. However, the InSTI do:@0.076190:0.274813:0.475923:0.274813:0.475923:0.259031:0.076190:0.259031:0.005125:0.012564:0.009903:0.003810:0.011188:0.009177:0.006426:0.003417:0.005866:0.003825:0.010326:0.005866:0.003825:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.003825:0.011188:0.009177:0.006441:0.003810:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.003825:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.003810:0.005125:0.009223:0.009827:0.003810:0.003417:0.009223:0.007529:0.006441:0.003417:0.003825:0.010357:0.009903
-:@0.475923:0.274813:0.480942:0.274813:0.480942:0.259031:0.475923:0.259031:0.005020
lutegravir (DTG) has been shown to be superior to efa-:@0.076190:0.288922:0.480972:0.288922:0.480972:0.273139:0.076190:0.273139:0.003024:0.009192:0.005125:0.009827:0.010175:0.004551:0.010326:0.008376:0.003024:0.004551:0.005095:0.005579:0.011249:0.006441:0.013184:0.005579:0.005095:0.009223:0.010326:0.005866:0.005095:0.010311:0.009827:0.009827:0.009223:0.005095:0.005866:0.009223:0.009903:0.012564:0.009223:0.005095:0.005125:0.009903:0.005095:0.010311:0.009827:0.005095:0.005866:0.009192:0.010311:0.009827:0.004551:0.003024:0.009903:0.004551:0.005095:0.005125:0.009903:0.005095:0.009827:0.004747:0.010326:0.005020
virenz (EFV)-based ART in clinical trials, driven largely by :@0.076190:0.303030:0.485115:0.303030:0.485115:0.287248:0.076190:0.287248:0.008376:0.003024:0.004551:0.009827:0.009223:0.006426:0.004400:0.005579:0.008104:0.007333:0.010614:0.005579:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.004415:0.011188:0.009177:0.006441:0.004400:0.003024:0.009223:0.004400:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.004415:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.004400:0.010357:0.004551:0.003024:0.008376:0.009827:0.009223:0.004400:0.003024:0.010326:0.004551:0.010175:0.009827:0.003024:0.008104:0.004400:0.010311:0.008104:0.004188
the superior tolerability of DTG, which also has a higher :@0.076190:0.317139:0.485145:0.317139:0.485145:0.301356:0.076190:0.301356:0.005125:0.009223:0.009827:0.004838:0.005866:0.009192:0.010311:0.009827:0.004551:0.003024:0.009903:0.004551:0.004838:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.010311:0.003024:0.003024:0.003024:0.005125:0.008104:0.004853:0.009903:0.004747:0.004838:0.011249:0.006441:0.013184:0.004188:0.004838:0.012564:0.009223:0.003024:0.009782:0.009223:0.004838:0.010326:0.003024:0.005866:0.009903:0.004853:0.009223:0.010326:0.005866:0.004853:0.010326:0.004838:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.004188
barrier  to  resistance.  DTG-based combination  ART  is :@0.076190:0.331247:0.485129:0.331272:0.485129:0.315490:0.076190:0.315465:0.010311:0.010326:0.004551:0.004551:0.003024:0.009827:0.004551:0.004188:0.002480:0.005125:0.009903:0.004188:0.002480:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.012639:0.006683:0.011249:0.006441:0.013184:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.006683:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.002480:0.011188:0.009177:0.006441:0.004188:0.002480:0.003024:0.005866:0.415441
5-7:@0.229308:0.325974:0.241936:0.325974:0.241936:0.316820:0.229308:0.316820:0.004858:0.002911:0.004858
available in the private sector and is already included :@0.076190:0.345381:0.485114:0.345381:0.485114:0.329598:0.076190:0.329598:0.010326:0.008376:0.010326:0.003024:0.003024:0.010326:0.010311:0.003024:0.009827:0.005397:0.003024:0.009223:0.005382:0.005125:0.009223:0.009827:0.005382:0.010311:0.004551:0.003024:0.008376:0.010326:0.005125:0.009827:0.005382:0.005866:0.009827:0.009782:0.005125:0.009903:0.004551:0.005367:0.010326:0.009223:0.010357:0.005382:0.003024:0.005866:0.005382:0.010326:0.003024:0.004551:0.009827:0.010326:0.010357:0.008104:0.005382:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.010357:0.004188
in the first-line regimen in the public sector in Botswana. :@0.076190:0.359489:0.485144:0.359489:0.485144:0.343707:0.076190:0.343707:0.003024:0.009223:0.004324:0.005125:0.009223:0.009827:0.004324:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004339:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004324:0.003024:0.009223:0.004324:0.005125:0.009223:0.009827:0.004324:0.010311:0.009192:0.010311:0.003024:0.003024:0.009782:0.004339:0.005866:0.009827:0.009782:0.005125:0.009903:0.004551:0.004324:0.003024:0.009223:0.004324:0.008678:0.009903:0.005125:0.005866:0.012564:0.010326:0.009223:0.010326:0.004188:0.004188
The WHO ART guideline and the 2019 south African ART :@0.076190:0.373598:0.485144:0.373598:0.485144:0.357815:0.076190:0.357815:0.006441:0.009223:0.009827:0.004279:0.014514:0.010326:0.013138:0.004294:0.011188:0.009177:0.006441:0.004279:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.004294:0.010326:0.009223:0.010357:0.004294:0.005125:0.009223:0.009827:0.004294:0.008376:0.008376:0.008376:0.008376:0.004309:0.007529:0.009903:0.009192:0.005125:0.009223:0.004279:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.009223:0.004294:0.011188:0.009177:0.006441:0.004188
guideline for  treatment  of  adults, which  will soon  be :@0.076190:0.387706:0.485144:0.387706:0.485144:0.371924:0.076190:0.371924:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.007680:0.004747:0.009903:0.004551:0.004188:0.003477:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.003477:0.009903:0.004747:0.004188:0.003477:0.010326:0.010357:0.009192:0.003024:0.005125:0.005866:0.004188:0.007680:0.012564:0.009223:0.003024:0.009782:0.009223:0.004188:0.003477:0.012564:0.003024:0.003024:0.003024:0.007680:0.005866:0.009903:0.009903:0.009223:0.004188:0.003477:0.010311:0.009827:0.004188
rolled out, recommends use of DTG-based first-line ART :@0.076190:0.401815:0.485159:0.401815:0.485159:0.386032:0.076190:0.386032:0.004551:0.009903:0.003024:0.003024:0.009827:0.010357:0.005156:0.009903:0.009192:0.005125:0.004188:0.005140:0.004551:0.009827:0.009782:0.009888:0.014182:0.014182:0.009827:0.009223:0.010357:0.005866:0.005156:0.009192:0.005866:0.009827:0.005156:0.009903:0.004747:0.005156:0.011249:0.006441:0.013184:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.005156:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005140:0.011188:0.009177:0.006441:0.004188
for all men, for women and adolescent girls on effec-:@0.076190:0.415923:0.480956:0.415923:0.480956:0.400141:0.076190:0.400141:0.004747:0.009903:0.004551:0.005987:0.010326:0.003024:0.003024:0.006002:0.014182:0.009827:0.009223:0.004188:0.006002:0.004747:0.009903:0.004536:0.006002:0.012564:0.009903:0.014182:0.009827:0.009223:0.006002:0.010326:0.009223:0.010357:0.006002:0.010326:0.010357:0.009903:0.003024:0.009827:0.005866:0.009782:0.009827:0.009223:0.005125:0.006002:0.010175:0.003024:0.004551:0.003024:0.005866:0.006002:0.009903:0.009223:0.006002:0.009827:0.004747:0.004747:0.009827:0.009782:0.005020
tive contraception or not  of childbearing potential, :@0.076190:0.430032:0.485159:0.430032:0.485159:0.414249:0.076190:0.414249:0.005125:0.003024:0.008376:0.009827:0.009344:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.009782:0.009827:0.010311:0.005125:0.003024:0.009903:0.009223:0.009344:0.009903:0.004551:0.009344:0.009223:0.009903:0.005125:0.004188:0.005140:0.009903:0.004747:0.009344:0.009782:0.009223:0.003024:0.003024:0.010357:0.010311:0.009827:0.010326:0.004551:0.003024:0.009223:0.010175:0.009344:0.010311:0.009903:0.005125:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.004188:0.004188
pregnant women (in second and third trimesters) and :@0.076190:0.444140:0.485129:0.444140:0.485129:0.428358:0.076190:0.428358:0.010311:0.004551:0.009827:0.010175:0.009223:0.010326:0.009223:0.005125:0.005972:0.012564:0.009903:0.014182:0.009827:0.009223:0.005987:0.005579:0.003024:0.009223:0.005987:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.005987:0.010326:0.009223:0.010357:0.005987:0.005125:0.009223:0.003024:0.004551:0.010357:0.005987:0.005125:0.004551:0.003024:0.014182:0.009827:0.005866:0.005125:0.009827:0.004551:0.005866:0.005579:0.005987:0.010326:0.009223:0.010357:0.004188
breastfeeding women.  DTG may increase the risk of :@0.076190:0.458249:0.485127:0.458293:0.485127:0.442511:0.076190:0.442466:0.010311:0.004551:0.009827:0.010326:0.005866:0.005125:0.004747:0.009827:0.009827:0.010357:0.003024:0.009223:0.010175:0.006184:0.012564:0.009903:0.014182:0.009827:0.009223:0.004188:0.012622:0.006184:0.011249:0.006441:0.013184:0.006184:0.014182:0.010326:0.008104:0.006184:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.006184:0.005125:0.009223:0.009827:0.006184:0.004551:0.003024:0.005866:0.007590:0.006184:0.009903:0.004747:0.249106
5-7:@0.245438:0.452995:0.258066:0.452995:0.258066:0.443841:0.245438:0.443841:0.004858:0.002911:0.004858
neural tube defects, and should currently be avoided in :@0.076188:0.472402:0.485127:0.472402:0.485127:0.456619:0.076188:0.456619:0.009223:0.009827:0.009192:0.004551:0.010326:0.003024:0.003629:0.005125:0.009192:0.010311:0.009827:0.003629:0.010357:0.009827:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188:0.003629:0.010326:0.009223:0.010357:0.003629:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003629:0.009782:0.009192:0.004551:0.004551:0.009827:0.009223:0.005125:0.003024:0.008104:0.003629:0.010311:0.009827:0.003629:0.010326:0.008376:0.009903:0.003024:0.010357:0.009827:0.010357:0.003629:0.003024:0.009223:0.004188
periconception and in the first trimester of pregnancy.:@0.076188:0.486511:0.470991:0.486511:0.470991:0.470728:0.076188:0.470728:0.010311:0.009827:0.004551:0.003024:0.009782:0.009903:0.009223:0.009782:0.009827:0.010311:0.005125:0.003024:0.009903:0.009223:0.004188:0.010326:0.009223:0.010357:0.004188:0.003024:0.009223:0.004188:0.005125:0.009223:0.009827:0.004188:0.003681:0.003681:0.004551:0.005866:0.005125:0.004188:0.005125:0.004551:0.003024:0.014182:0.009827:0.005866:0.005125:0.009827:0.004551:0.004188:0.009903:0.004747:0.004188:0.010311:0.004551:0.009827:0.010175:0.009223:0.010326:0.009223:0.009782:0.008104:0.004188
6:@0.470939:0.481222:0.475797:0.481222:0.475797:0.472068:0.470939:0.472068:0.004858
Regarding NNRTI-based first-line regimens, EFV is pre:@0.533333:0.084931:0.918778:0.084931:0.918778:0.069149:0.533333:0.069149:0.009177:0.009827:0.010175:0.010326:0.004551:0.010357:0.003024:0.009223:0.010175:0.005322:0.011188:0.011188:0.009177:0.006441:0.003417:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.005322:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005337:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.005866:0.004188:0.005322:0.008104:0.007333:0.010614:0.005337:0.003024:0.005866:0.005337:0.010311:0.004551:0.009827
-:@0.918778:0.084931:0.923797:0.084931:0.923797:0.069149:0.918778:0.069149:0.005020
ferred.  Both severe rash and hepatotoxicity  are more :@0.519045:0.099271:0.928015:0.099271:0.928015:0.083488:0.519045:0.083488:0.004747:0.009827:0.004551:0.004551:0.009827:0.010357:0.004188:0.004188:0.002434:0.008678:0.009903:0.005125:0.009223:0.006637:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.006637:0.004551:0.010326:0.005866:0.009223:0.006637:0.010326:0.009223:0.010357:0.006637:0.009223:0.009827:0.010311:0.010326:0.005125:0.009903:0.005125:0.009903:0.007257:0.003024:0.009782:0.003024:0.005125:0.008104:0.004188:0.002434:0.010326:0.004551:0.009827:0.006637:0.014182:0.009903:0.004551:0.009827:0.004188
common with nevirapine (NVp) use with baseline CD4 :@0.519045:0.113610:0.928015:0.113610:0.928015:0.097828:0.519045:0.097828:0.009782:0.009903:0.014182:0.014182:0.009903:0.009223:0.005685:0.012564:0.003024:0.005125:0.009223:0.005700:0.009223:0.009827:0.008376:0.003024:0.004551:0.010326:0.010311:0.003024:0.009223:0.009827:0.005700:0.005579:0.011188:0.010614:0.008950:0.005579:0.005700:0.009192:0.005866:0.009827:0.005700:0.012564:0.003024:0.005125:0.009223:0.005700:0.010311:0.010326:0.005866:0.009827:0.003024:0.003024:0.009223:0.009827:0.005700:0.012292:0.011249:0.008376:0.004188
cell counts above >250 cells/mm  in women and >400 :@0.519045:0.127950:0.927970:0.127959:0.927970:0.112176:0.519045:0.112167:0.009782:0.009827:0.003024:0.003024:0.005443:0.009782:0.009903:0.009192:0.009223:0.005125:0.005866:0.005428:0.010326:0.010311:0.009903:0.008376:0.009827:0.005428:0.009162:0.008376:0.008376:0.008376:0.005443:0.009782:0.009827:0.003024:0.003024:0.005866:0.006607:0.014182:0.014182:0.004869:0.005428:0.003024:0.009223:0.005428:0.012564:0.009903:0.014182:0.009827:0.009223:0.005428:0.010326:0.009223:0.010357:0.005428:0.009162:0.008376:0.008376:0.008376:0.238844
3:@0.765071:0.122660:0.769929:0.122660:0.769929:0.113506:0.765071:0.113506:0.004858
cells/mm:@0.519046:0.142298:0.585539:0.142298:0.585539:0.126516:0.519046:0.126516:0.009782:0.009827:0.003024:0.003024:0.005866:0.006607:0.014182:0.014182
3:@0.585547:0.137003:0.590405:0.137003:0.590405:0.127849:0.585547:0.127849:0.004858
 in men. A PI may be used in first-line therapy if :@0.590407:0.142301:0.927985:0.142301:0.927985:0.126519:0.590407:0.126519:0.003795:0.003024:0.009223:0.003795:0.014182:0.009827:0.009223:0.004188:0.003780:0.011188:0.003780:0.008950:0.003417:0.003780:0.014182:0.010326:0.008104:0.003795:0.010311:0.009827:0.003795:0.009192:0.005866:0.009827:0.010357:0.003795:0.003024:0.009223:0.003795:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.003780:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.003780:0.003024:0.004747:0.004188
there are contra-indications to InsTIs and NNRTIs.:@0.519045:0.156641:0.872528:0.156641:0.872528:0.140858:0.519045:0.140858:0.005125:0.009223:0.009827:0.004551:0.009827:0.004188:0.010326:0.004551:0.009827:0.004188:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.005125:0.009903:0.004188:0.003417:0.009223:0.007529:0.006441:0.003417:0.005866:0.004188:0.010326:0.009223:0.010357:0.004188:0.011188:0.011188:0.009177:0.006441:0.003417:0.005866:0.004188
5-7:@0.872484:0.151345:0.885112:0.151345:0.885112:0.142191:0.872484:0.142191:0.004858:0.002911:0.004858
The  two  drug  NRTI  combinations that  are  recom-:@0.533333:0.170986:0.923812:0.170986:0.923812:0.155204:0.533333:0.155204:0.006441:0.009223:0.009827:0.004188:0.005125:0.005125:0.012564:0.009903:0.004188:0.005125:0.010357:0.004551:0.009192:0.010175:0.004188:0.005125:0.011188:0.009177:0.006441:0.003417:0.004188:0.005125:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.009328:0.005125:0.009223:0.010326:0.005125:0.004188:0.005125:0.010326:0.004551:0.009827:0.004188:0.005125:0.004551:0.009827:0.009782:0.009903:0.014212:0.005020
mended for  use with the  InsTI or  NNRTI  include lami-:@0.519045:0.185326:0.923797:0.185326:0.923797:0.169543:0.519045:0.169543:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.007439:0.004747:0.009903:0.004551:0.004188:0.003235:0.009192:0.005866:0.009827:0.007439:0.012564:0.003024:0.005125:0.009223:0.007439:0.005125:0.009223:0.009827:0.004188:0.003235:0.003417:0.009223:0.007529:0.006441:0.003417:0.007439:0.009903:0.004551:0.004188:0.003235:0.011188:0.011188:0.009177:0.006441:0.003417:0.004188:0.003235:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.007439:0.003024:0.010326:0.014182:0.003024:0.005020
vudine (3TC) plus TDF, AZT or abacavir (ABC). Emtricit-:@0.519045:0.199665:0.923812:0.199665:0.923812:0.183882:0.519045:0.183882:0.008376:0.009192:0.010357:0.003024:0.009223:0.009827:0.005881:0.005579:0.008376:0.006441:0.012292:0.005579:0.005896:0.010311:0.003024:0.009192:0.005866:0.005896:0.006441:0.011249:0.007333:0.004188:0.005881:0.011188:0.007257:0.006441:0.005881:0.009903:0.004551:0.005881:0.010326:0.010311:0.010326:0.009782:0.010326:0.008376:0.003024:0.004551:0.005896:0.005579:0.011188:0.008678:0.012292:0.005579:0.004188:0.005881:0.008104:0.014182:0.005125:0.004551:0.003024:0.009782:0.003024:0.005125:0.005020
abine (FTC), which is similar to 3TC, and combined with :@0.519045:0.214005:0.927985:0.214005:0.927985:0.198222:0.519045:0.198222:0.010326:0.010311:0.003024:0.009223:0.009827:0.004581:0.005579:0.007333:0.006441:0.012292:0.005579:0.004188:0.004566:0.012564:0.009223:0.003024:0.009782:0.009223:0.004581:0.003024:0.005866:0.004581:0.005866:0.003024:0.014182:0.003024:0.003024:0.010326:0.004551:0.004581:0.005125:0.009903:0.004566:0.008376:0.006441:0.012292:0.004188:0.004566:0.010326:0.009223:0.010357:0.004566:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.004566:0.012564:0.003024:0.005125:0.009223:0.004188
TDF in a fixed-dose combination pill or efavirenz (EFV) :@0.519045:0.228344:0.927970:0.228344:0.927970:0.212561:0.519045:0.212561:0.006441:0.011249:0.007333:0.006244:0.003024:0.009223:0.006244:0.010326:0.006244:0.003681:0.003681:0.007257:0.009827:0.010357:0.005020:0.010357:0.009903:0.005866:0.009827:0.006244:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.006244:0.010311:0.003024:0.003024:0.003024:0.006259:0.009903:0.004551:0.006244:0.009827:0.004747:0.010326:0.008376:0.003024:0.004551:0.009827:0.009223:0.006426:0.006244:0.005579:0.008104:0.007333:0.010614:0.005579:0.004188
as a triple-drug combination pill can also be used.:@0.519045:0.242683:0.885652:0.242683:0.885652:0.226901:0.519045:0.226901:0.010326:0.005866:0.004188:0.010326:0.004188:0.005125:0.004551:0.003024:0.010311:0.003024:0.009827:0.005020:0.010357:0.004551:0.009192:0.010175:0.004188:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.010311:0.003024:0.003024:0.003024:0.004188:0.009782:0.010326:0.009223:0.004188:0.010326:0.003024:0.005866:0.009903:0.004188:0.010311:0.009827:0.004188:0.009192:0.005866:0.009827:0.010357:0.004188
5-7,9-10:@0.885647:0.237400:0.918189:0.237400:0.918189:0.228246:0.885647:0.228246:0.004858:0.002911:0.004858:0.002429:0.004858:0.002911:0.004858:0.004858
If TDF is unavailable  or contra-indicated in patients :@0.533333:0.257041:0.927985:0.257041:0.927985:0.241258:0.533333:0.241258:0.003417:0.004747:0.007272:0.006441:0.011249:0.007333:0.007272:0.003024:0.005866:0.007272:0.009192:0.009223:0.010326:0.008376:0.010326:0.003024:0.003024:0.010326:0.010311:0.003024:0.009827:0.004188:0.003099:0.009903:0.004551:0.007272:0.009782:0.009903:0.009223:0.005125:0.004536:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.007272:0.003024:0.009223:0.007272:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188
with a creatinine clearance <50 ml/min, AZT should be :@0.519045:0.271381:0.928000:0.271381:0.928000:0.255598:0.519045:0.255598:0.012564:0.003024:0.005125:0.009223:0.005125:0.010326:0.005125:0.009782:0.004551:0.009827:0.010326:0.005125:0.003024:0.009223:0.003024:0.009223:0.009827:0.005110:0.009782:0.003024:0.009827:0.010326:0.004551:0.010326:0.009223:0.009782:0.009827:0.005125:0.009162:0.008376:0.008376:0.005125:0.014182:0.003024:0.006607:0.014182:0.003024:0.009223:0.004188:0.005125:0.011188:0.007257:0.006441:0.005110:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005125:0.010311:0.009827:0.004188
used, provided that haemoglobin >10 g/dL.  ABC is an :@0.519045:0.285720:0.927995:0.285726:0.927995:0.269943:0.519045:0.269937:0.009192:0.005866:0.009827:0.010357:0.004188:0.005004:0.010311:0.004551:0.009903:0.008376:0.003024:0.010357:0.009827:0.010357:0.005004:0.005125:0.009223:0.010326:0.005125:0.005004:0.009223:0.010326:0.009827:0.014182:0.009903:0.010175:0.003024:0.009903:0.010311:0.003024:0.009223:0.005004:0.009162:0.008376:0.008376:0.005004:0.010175:0.006607:0.010357:0.006985:0.004188:0.004848:0.005004:0.011188:0.008678:0.012292:0.005004:0.003024:0.005866:0.005004:0.010326:0.009223:0.032219
9:@0.843337:0.280427:0.848195:0.280427:0.848195:0.271273:0.843337:0.271273:0.004858
option in patients with renal failure where TDF and AZT :@0.519040:0.300065:0.927995:0.300065:0.927995:0.284283:0.519040:0.284283:0.009903:0.010311:0.005125:0.003024:0.009903:0.009223:0.005413:0.003024:0.009223:0.005428:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005428:0.012564:0.003024:0.005125:0.009223:0.005428:0.004551:0.009827:0.009223:0.010326:0.003024:0.005428:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005428:0.012564:0.009223:0.009827:0.004551:0.009827:0.005413:0.006441:0.011249:0.007333:0.005428:0.010326:0.009223:0.010357:0.005428:0.011188:0.007257:0.006441:0.004188
cannot be used. It must not be used in patients with :@0.519040:0.314405:0.927965:0.314405:0.927965:0.298622:0.519040:0.298622:0.009782:0.010326:0.009223:0.009223:0.009903:0.005125:0.006804:0.010311:0.009827:0.006804:0.009192:0.005866:0.009827:0.010357:0.004188:0.006804:0.003417:0.005125:0.006804:0.014182:0.009192:0.005866:0.005125:0.006804:0.009223:0.009903:0.005125:0.006804:0.010311:0.009827:0.006804:0.009192:0.005866:0.009827:0.010357:0.006804:0.003024:0.009223:0.006804:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006804:0.012564:0.003024:0.005125:0.009223:0.004188
baseline viral loads >100 000 copies/ml.:@0.519040:0.328744:0.806317:0.328744:0.806317:0.312962:0.519040:0.312962:0.010311:0.010326:0.005866:0.009827:0.003024:0.003024:0.009223:0.009827:0.004188:0.008376:0.003024:0.004551:0.010326:0.003024:0.004188:0.003024:0.009903:0.010326:0.010357:0.005866:0.004188:0.009162:0.008376:0.008376:0.008376:0.004188:0.008376:0.008376:0.008376:0.004188:0.009782:0.009903:0.010311:0.003024:0.009827:0.005866:0.006607:0.014182:0.003024:0.004188
5,6:@0.806353:0.323455:0.818498:0.323455:0.818498:0.314301:0.806353:0.314301:0.004858:0.002429:0.004858
stavudine (d4T) may be used in the short term (three :@0.533333:0.343096:0.928000:0.343096:0.928000:0.327313:0.533333:0.327313:0.007529:0.005125:0.010326:0.008376:0.009192:0.010357:0.003024:0.009223:0.009827:0.004929:0.005579:0.010357:0.008376:0.006441:0.005579:0.004929:0.014182:0.010326:0.008104:0.004929:0.010311:0.009827:0.004914:0.009192:0.005866:0.009827:0.010357:0.004914:0.003024:0.009223:0.004914:0.005125:0.009223:0.009827:0.004914:0.005866:0.009223:0.009903:0.004551:0.005125:0.004914:0.005125:0.009827:0.004551:0.014182:0.004914:0.005579:0.005125:0.009223:0.004551:0.009827:0.009827:0.004188
to six months) in patients with contra-indications to other :@0.519045:0.357435:0.928000:0.357435:0.928000:0.341653:0.519045:0.341653:0.005125:0.009903:0.003372:0.005866:0.003024:0.007257:0.003387:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.005579:0.003372:0.003024:0.009223:0.003387:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003387:0.012564:0.003024:0.005125:0.009223:0.003372:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.003372:0.005125:0.009903:0.003372:0.009903:0.005125:0.009223:0.009827:0.004551:0.004188
NRTIs, and then switched to ABC, AZT or TDF, depend-:@0.519045:0.371775:0.923812:0.371775:0.923812:0.355992:0.519045:0.355992:0.011188:0.009177:0.006441:0.003417:0.005866:0.004188:0.005609:0.010326:0.009223:0.010357:0.005624:0.005125:0.009223:0.009827:0.009223:0.005624:0.005866:0.012564:0.003024:0.005125:0.009782:0.009223:0.009827:0.010357:0.005624:0.005125:0.009903:0.005624:0.011188:0.008678:0.012292:0.004188:0.005624:0.011188:0.007257:0.006441:0.005609:0.009903:0.004551:0.005609:0.006441:0.011249:0.007333:0.004188:0.005624:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.005020
ing on resolution of the anaemia or renal dysfunction, :@0.519045:0.386114:0.928000:0.386114:0.928000:0.370331:0.519045:0.370331:0.003024:0.009223:0.010175:0.005927:0.009903:0.009223:0.005927:0.004551:0.009827:0.005866:0.009903:0.003024:0.009192:0.005125:0.003024:0.009903:0.009223:0.005912:0.009903:0.004747:0.005927:0.005125:0.009223:0.009827:0.005927:0.010326:0.009223:0.010326:0.009827:0.014182:0.003024:0.010326:0.005927:0.009903:0.004551:0.005912:0.004551:0.009827:0.009223:0.010326:0.003024:0.005927:0.010357:0.008104:0.005866:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188
whilst monitoring for adverse events, such as the hyper-:@0.519045:0.400453:0.923797:0.400453:0.923797:0.384671:0.519045:0.384671:0.012564:0.009223:0.003024:0.003024:0.005866:0.005125:0.004430:0.014182:0.009903:0.009223:0.003024:0.005125:0.009903:0.004551:0.003024:0.009223:0.010175:0.004415:0.004747:0.009903:0.004551:0.004415:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.004430:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004188:0.004415:0.005866:0.009192:0.009782:0.009223:0.004415:0.010326:0.005866:0.004430:0.005125:0.009223:0.009827:0.004415:0.009223:0.008104:0.010311:0.009827:0.004551:0.005020
lactataemia syndromes and peripheral neuropathy.:@0.519045:0.414793:0.899516:0.414793:0.899516:0.399010:0.519045:0.399010:0.003024:0.010326:0.009782:0.005125:0.010326:0.005125:0.010326:0.009827:0.014182:0.003024:0.010326:0.004097:0.005866:0.008104:0.009223:0.010357:0.004551:0.009903:0.014182:0.009827:0.005866:0.004082:0.010326:0.009223:0.010357:0.004082:0.010311:0.009827:0.004551:0.003024:0.010311:0.009223:0.009827:0.004551:0.010326:0.003024:0.004082:0.009223:0.009827:0.009192:0.004551:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.004188
5,6,11:@0.899514:0.409509:0.923804:0.409509:0.923804:0.400355:0.899514:0.400355:0.004858:0.002429:0.004858:0.002429:0.004858:0.004858
 :@0.923809:0.414808:0.927997:0.414808:0.927997:0.399025:0.923809:0.399025:0.004188
A  non-TDF-based regimen  must be considered  if ne-:@0.519042:0.429148:0.923809:0.429148:0.923809:0.413365:0.519042:0.413365:0.011188:0.004188:0.003462:0.009223:0.009903:0.009223:0.005020:0.006441:0.011249:0.007333:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.007665:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004188:0.003462:0.014182:0.009192:0.005866:0.005125:0.007665:0.010311:0.009827:0.007665:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.004188:0.003462:0.003024:0.004747:0.007665:0.009223:0.009827:0.005020
phrotoxic drugs are to be used, especially in the case of :@0.519042:0.443487:0.927997:0.443487:0.927997:0.427704:0.519042:0.427704:0.010311:0.009223:0.004551:0.009903:0.005125:0.009903:0.007257:0.003024:0.009782:0.003613:0.010357:0.004551:0.009192:0.010175:0.005866:0.003629:0.010326:0.004551:0.009827:0.003629:0.005125:0.009903:0.003613:0.010311:0.009827:0.003629:0.009192:0.005866:0.009827:0.010357:0.004188:0.003629:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.008104:0.003644:0.003024:0.009223:0.003629:0.005125:0.009223:0.009827:0.003613:0.009782:0.010326:0.005866:0.009827:0.003629:0.009903:0.004747:0.004188
multidrug-resistant TB (MDR)-TB, where aminoglycosides :@0.519042:0.457826:0.927982:0.457826:0.927982:0.442044:0.519042:0.442044:0.014182:0.009192:0.003024:0.005125:0.003024:0.010357:0.004551:0.009192:0.010175:0.005020:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.005125:0.004611:0.006441:0.008678:0.004626:0.005579:0.013894:0.011249:0.009177:0.005579:0.005020:0.006441:0.008678:0.004188:0.004626:0.012564:0.009223:0.009827:0.004551:0.009827:0.004611:0.010326:0.014182:0.003024:0.009223:0.009903:0.010175:0.003024:0.008104:0.009782:0.009903:0.005866:0.003024:0.010357:0.009827:0.005866:0.004188
are used.  The 2019 National south African ART recom-:@0.519042:0.472166:0.923803:0.472178:0.923803:0.456395:0.519042:0.456383:0.010326:0.004551:0.009827:0.005095:0.009192:0.005866:0.009827:0.010357:0.004188:0.004863:0.005095:0.006441:0.009223:0.009827:0.005095:0.008376:0.008376:0.008376:0.008376:0.005110:0.011188:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.005095:0.007529:0.009903:0.009192:0.005125:0.009223:0.005095:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.009223:0.005095:0.011188:0.009177:0.006441:0.005095:0.004551:0.009827:0.009782:0.009903:0.014151:-0.206921
5:@0.588275:0.466879:0.593133:0.466879:0.593133:0.457725:0.588275:0.457725:0.004858
mendations are listed in Table 3.:@0.519037:0.486517:0.753699:0.486517:0.753699:0.470735:0.519037:0.470735:0.014182:0.009827:0.009223:0.010357:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.010326:0.004551:0.009827:0.004188:0.003024:0.003024:0.005866:0.005125:0.009827:0.010357:0.004188:0.003024:0.009223:0.004188:0.006441:0.010326:0.010311:0.003024:0.009827:0.004188:0.008376:0.004188
6:@0.753702:0.481222:0.758560:0.481222:0.758560:0.472068:0.753702:0.472068:0.004858
table 3. the south African national antiretroviral therapy guidelines  :@0.077030:0.524949:0.572966:0.524949:0.572966:0.508451:0.077030:0.508451:0.006350:0.009979:0.009979:0.003629:0.009676:0.004233:0.008467:0.004233:0.004233:0.006350:0.009071:0.009676:0.004233:0.007862:0.009676:0.009071:0.004536:0.009071:0.004233:0.011188:0.004233:0.004838:0.003629:0.009676:0.009979:0.009071:0.004233:0.009071:0.009979:0.004536:0.003629:0.009676:0.009071:0.009979:0.003629:0.004233:0.009979:0.009071:0.004536:0.003629:0.004838:0.009676:0.004536:0.004838:0.009676:0.008467:0.003629:0.004838:0.009979:0.003629:0.004233:0.004536:0.009071:0.009676:0.004838:0.009979:0.009979:0.008769:0.004233:0.009979:0.009071:0.003629:0.009979:0.009676:0.003629:0.003629:0.009071:0.009676:0.006652:0.004870:0.004233
6:@0.563822:0.519650:0.568733:0.519650:0.568733:0.510081:0.563822:0.510081:0.004911
first-line therapy:@0.082070:0.543798:0.189046:0.543798:0.189046:0.529133:0.082070:0.529133:0.006451:0.003225:0.004301:0.005913:0.004032:0.005644:0.003225:0.003225:0.008063:0.008601:0.003763:0.004032:0.008063:0.008601:0.004301:0.008870:0.008870:0.007795
All new patients needing treatment, includ-:@0.082070:0.559192:0.364171:0.559192:0.364171:0.545163:0.082070:0.545163:0.009945:0.002688:0.002688:0.003723:0.008198:0.008735:0.011168:0.003723:0.009165:0.009179:0.004556:0.002688:0.008735:0.008198:0.004556:0.005214:0.003723:0.008198:0.008735:0.008735:0.009206:0.002688:0.008198:0.009045:0.003723:0.004556:0.004045:0.008735:0.009179:0.004556:0.012606:0.008735:0.008198:0.004556:0.003723:0.003723:0.002688:0.008198:0.008695:0.002688:0.008171:0.009179:0.004462
ing all men, women and adolescent girls on  +DTG:@0.082070:0.572020:0.418143:0.572020:0.418143:0.557991:0.082070:0.557991:0.002688:0.008198:0.009045:0.003723:0.009179:0.002688:0.002688:0.003723:0.012606:0.008735:0.008198:0.003723:0.003723:0.011168:0.008803:0.012606:0.008735:0.008198:0.003723:0.009179:0.008198:0.009206:0.003723:0.009179:0.009206:0.008803:0.002688:0.008735:0.005214:0.008695:0.008735:0.008198:0.004556:0.003723:0.009045:0.002688:0.004045:0.002688:0.005214:0.003723:0.008803:0.008198:0.003723:0.012176:0.008144:0.009999:0.005725:0.011719
effective contraception or not of childbear-:@0.082070:0.584848:0.367477:0.584848:0.367477:0.570819:0.082070:0.570819:0.008735:0.004220:0.004220:0.008735:0.008695:0.004556:0.002688:0.007445:0.008735:0.003723:0.008695:0.008803:0.008198:0.004556:0.004045:0.009179:0.008695:0.008735:0.009165:0.004556:0.002688:0.008803:0.008198:0.003723:0.008803:0.004045:0.003723:0.008198:0.008803:0.004556:0.003723:0.008803:0.004220:0.003723:0.008695:0.008198:0.002688:0.002688:0.009206:0.009165:0.008735:0.009179:0.004005:0.004462
ing potential, pregnant women (in 2  and :@0.082070:0.597677:0.360924:0.597677:0.360924:0.583648:0.082070:0.583648:0.002688:0.008198:0.009045:0.003723:0.009165:0.008803:0.004556:0.008735:0.008198:0.004556:0.002688:0.009179:0.002688:0.003723:0.003723:0.009165:0.004045:0.008735:0.009045:0.008198:0.009179:0.008198:0.004556:0.003723:0.011168:0.008803:0.012606:0.008735:0.008198:0.003723:0.004959:0.002688:0.008198:0.003723:0.007445:0.010071:0.003723:0.009179:0.008198:0.009206:0.003723
nd:@0.316802:0.592967:0.326896:0.592967:0.326896:0.584830:0.316802:0.584830:0.004755:0.005339
3  trimesters) and breastfeeding women :@0.082075:0.610505:0.348985:0.610505:0.348985:0.596476:0.082075:0.596476:0.007445:0.007682:0.003723:0.004556:0.004045:0.002688:0.012606:0.008735:0.005214:0.004556:0.008735:0.004045:0.005214:0.004959:0.003723:0.009179:0.008198:0.009206:0.003723:0.009165:0.004045:0.008735:0.009179:0.005214:0.004556:0.004220:0.008735:0.008735:0.009206:0.002688:0.008198:0.009045:0.003723:0.011168:0.008803:0.012606:0.008735:0.008198:0.003723
rd:@0.089518:0.605795:0.097203:0.605795:0.097203:0.597658:0.089518:0.597658:0.002346:0.005339
(documented consent to receive DTG in all :@0.082070:0.623333:0.367719:0.623333:0.367719:0.609304:0.082070:0.609304:0.004959:0.009206:0.008803:0.008695:0.008171:0.012606:0.008735:0.008198:0.004556:0.008735:0.009206:0.003723:0.008695:0.008803:0.008198:0.005214:0.008735:0.008198:0.004556:0.003723:0.004556:0.008803:0.003723:0.004045:0.008735:0.008695:0.008735:0.002688:0.007445:0.008735:0.003723:0.009999:0.005725:0.011719:0.003723:0.002688:0.008198:0.003723:0.009179:0.002688:0.002688:0.003723
women):@0.082070:0.636161:0.136539:0.636161:0.136539:0.622132:0.082070:0.622132:0.011168:0.008803:0.012606:0.008735:0.008198:0.004959
Pregnant women in first trimester, women :@0.082070:0.651555:0.353487:0.651555:0.353487:0.637526:0.082070:0.637526:0.007956:0.004045:0.008735:0.009045:0.008198:0.009179:0.008198:0.004556:0.003723:0.011168:0.008803:0.012606:0.008735:0.008198:0.003723:0.002688:0.008198:0.003723:0.003272:0.003272:0.004045:0.005214:0.004556:0.003723:0.004556:0.004045:0.002688:0.012606:0.008735:0.005214:0.004556:0.008735:0.004045:0.003723:0.003723:0.011168:0.008803:0.012606:0.008735:0.008198:0.003723
who wish to become pregnant and/or not :@0.082070:0.664384:0.361644:0.664384:0.361644:0.650355:0.082070:0.650355:0.011168:0.008198:0.008803:0.003723:0.011168:0.002688:0.005214:0.008198:0.003723:0.004556:0.008803:0.003723:0.009165:0.008735:0.008695:0.008803:0.012606:0.008735:0.003723:0.009165:0.004045:0.008735:0.009045:0.008198:0.009179:0.008198:0.004556:0.003723:0.009179:0.008198:0.009206:0.005873:0.008803:0.004045:0.003723:0.008198:0.008803:0.004556:0.003723
using reliable contraception:@0.082070:0.677212:0.265071:0.677212:0.265071:0.663183:0.082070:0.663183:0.008171:0.005214:0.002688:0.008198:0.009045:0.003723:0.004045:0.008735:0.002688:0.002688:0.009179:0.009165:0.002688:0.008735:0.003723:0.008695:0.008803:0.008198:0.004556:0.004045:0.009179:0.008695:0.008735:0.009165:0.004556:0.002688:0.008803:0.008198
TDF + FTC/3TC:@0.382556:0.559192:0.473525:0.559192:0.473525:0.545163:0.382556:0.545163:0.005725:0.009999:0.006518:0.003723:0.008144:0.003723:0.006518:0.005725:0.010926:0.005873:0.007445:0.005725:0.010926
TDF + FTC/3TC:@0.382556:0.651555:0.473525:0.651555:0.473525:0.637526:0.382556:0.637526:0.005725:0.009999:0.006518:0.003723:0.008144:0.003723:0.006518:0.005725:0.010926:0.005873:0.007445:0.005725:0.010926
+EFV/NVp :@0.382556:0.664384:0.450786:0.664384:0.450786:0.650355:0.382556:0.650355:0.008144:0.007203:0.006518:0.009434:0.005873:0.009945:0.009434:0.007956:0.003723
Contra-indications to DTG (pregnant women in :@0.596910:0.559192:0.906803:0.559192:0.906803:0.545163:0.596910:0.545163:0.010926:0.008803:0.008198:0.004556:0.004045:0.009179:0.004462:0.002688:0.008198:0.009206:0.002688:0.008695:0.009179:0.004556:0.002688:0.008803:0.008198:0.005214:0.003723:0.004556:0.008803:0.003723:0.009999:0.005725:0.011719:0.003723:0.004959:0.009165:0.004045:0.008735:0.009045:0.008198:0.009179:0.008198:0.004556:0.003723:0.011168:0.008803:0.012606:0.008735:0.008198:0.003723:0.002688:0.008198:0.003723
first trimester, women planning pregnancy or not :@0.596910:0.572020:0.915969:0.572020:0.915969:0.557991:0.596910:0.557991:0.003272:0.003272:0.004045:0.005214:0.004556:0.003723:0.004556:0.004045:0.002688:0.012606:0.008735:0.005214:0.004556:0.008735:0.004045:0.003723:0.003723:0.011168:0.008803:0.012606:0.008735:0.008198:0.003723:0.009165:0.002688:0.009179:0.008198:0.008198:0.002688:0.008198:0.009045:0.003723:0.009165:0.004045:0.008735:0.009045:0.008198:0.009179:0.008198:0.008695:0.007203:0.003723:0.008803:0.004045:0.003723:0.008198:0.008803:0.004556:0.003723
using reliable contraception): use EFV:@0.596910:0.584848:0.841314:0.584848:0.841314:0.570819:0.596910:0.570819:0.008171:0.005214:0.002688:0.008198:0.009045:0.003723:0.004045:0.008735:0.002688:0.002688:0.009179:0.009165:0.002688:0.008735:0.003723:0.008695:0.008803:0.008198:0.004556:0.004045:0.009179:0.008695:0.008735:0.009165:0.004556:0.002688:0.008803:0.008198:0.004959:0.003723:0.003723:0.008171:0.005214:0.008735:0.003723:0.007203:0.006518:0.009434
Contra-indication to EFV (psychosis, shift work-:@0.596910:0.597677:0.896267:0.597677:0.896267:0.583648:0.596910:0.583648:0.010926:0.008803:0.008198:0.004556:0.004045:0.009179:0.004462:0.002688:0.008198:0.009206:0.002688:0.008695:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.004556:0.008803:0.003723:0.007203:0.006518:0.009434:0.003723:0.004959:0.009165:0.005214:0.007203:0.008695:0.008198:0.008803:0.005214:0.002688:0.005214:0.003723:0.003723:0.005214:0.008198:0.002688:0.004220:0.004556:0.003723:0.011168:0.008803:0.004045:0.006733:0.004462
ers): use NVp :@0.596910:0.610505:0.684211:0.610505:0.684211:0.596476:0.596910:0.596476:0.008735:0.004045:0.005214:0.004959:0.003723:0.003723:0.008171:0.005214:0.008735:0.003723:0.009945:0.009434:0.007956:0.003723
pre-existent liver disease or TB co-infection: EFV :@0.596910:0.623333:0.903779:0.623333:0.903779:0.609304:0.596910:0.609304:0.007956:0.004045:0.008735:0.004462:0.008735:0.006451:0.002688:0.005214:0.004556:0.008735:0.008198:0.004556:0.003723:0.002688:0.002688:0.007445:0.008735:0.004045:0.003723:0.009206:0.002688:0.005214:0.008735:0.009179:0.005214:0.008735:0.003723:0.008803:0.004045:0.003723:0.005725:0.007714:0.003723:0.008695:0.008803:0.004462:0.002688:0.008198:0.004220:0.008735:0.008695:0.004556:0.002688:0.008803:0.008198:0.003723:0.003723:0.007203:0.006518:0.009434:0.003723
preferred.:@0.596910:0.636161:0.661566:0.636161:0.661566:0.622132:0.596910:0.622132:0.009165:0.004045:0.008735:0.004220:0.008735:0.004045:0.004045:0.008735:0.009206:0.003723
Contra-indication to TDF (renal disease): use AZT :@0.596910:0.648990:0.913335:0.648990:0.913335:0.634961:0.596910:0.634961:0.010926:0.008803:0.008198:0.004556:0.004045:0.009179:0.004462:0.002688:0.008198:0.009206:0.002688:0.008695:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.004556:0.008803:0.003723:0.005725:0.009999:0.006518:0.003723:0.004959:0.004045:0.008735:0.008198:0.009179:0.002688:0.003723:0.009206:0.002688:0.005214:0.008735:0.009179:0.005214:0.008735:0.004959:0.003723:0.003723:0.008171:0.005214:0.008735:0.003723:0.009945:0.006451:0.005725:0.003723
or ABC.:@0.596910:0.661818:0.645788:0.661818:0.645788:0.647789:0.596910:0.647789:0.008803:0.004045:0.003723:0.009945:0.007714:0.010926:0.003723
Contra-indication to TDF (renal disease) and AZT :@0.596910:0.674646:0.914074:0.674646:0.914074:0.660617:0.596910:0.660617:0.010926:0.008803:0.008198:0.004556:0.004045:0.009179:0.004462:0.002688:0.008198:0.009206:0.002688:0.008695:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.004556:0.008803:0.003723:0.005725:0.009999:0.006518:0.003723:0.004959:0.004045:0.008735:0.008198:0.009179:0.002688:0.003723:0.009206:0.002688:0.005214:0.008735:0.009179:0.005214:0.008735:0.004959:0.003723:0.009179:0.008198:0.009206:0.003723:0.009945:0.006451:0.005725:0.003723
(anaemia): use d4T or ABC.:@0.596910:0.687474:0.774858:0.687474:0.774858:0.673445:0.596910:0.673445:0.004959:0.009179:0.008198:0.009179:0.008735:0.012606:0.002688:0.009179:0.004959:0.003723:0.003723:0.008171:0.005214:0.008735:0.003723:0.009206:0.007445:0.005725:0.003723:0.008803:0.004045:0.003723:0.009945:0.007714:0.010926:0.003723
second-line therapy:@0.082070:0.702868:0.214849:0.702868:0.214849:0.688203:0.082070:0.688203:0.006988:0.008601:0.008601:0.008601:0.008063:0.008870:0.005644:0.003225:0.003225:0.008063:0.008601:0.003763:0.004032:0.008063:0.008601:0.004301:0.008870:0.008870:0.007795
Failing on a DTG-based first-line regimen :@0.082070:0.718262:0.346176:0.718262:0.346176:0.704233:0.082070:0.704233:0.006518:0.009179:0.002688:0.002688:0.002688:0.008198:0.009045:0.003723:0.008803:0.008198:0.003723:0.009179:0.003723:0.009999:0.005725:0.011719:0.004462:0.009165:0.009179:0.005214:0.008735:0.009206:0.003723:0.003272:0.003272:0.004045:0.005214:0.004556:0.004462:0.002688:0.002688:0.008198:0.008735:0.003723:0.004045:0.008735:0.009045:0.002688:0.012606:0.008735:0.008198:0.003723
(may require drug-resistance testing) or pa-:@0.082070:0.731091:0.363983:0.731091:0.363983:0.717062:0.082070:0.717062:0.004959:0.012606:0.009179:0.007203:0.003723:0.004045:0.008735:0.009165:0.008171:0.002688:0.004045:0.008735:0.003723:0.009206:0.004045:0.008171:0.009045:0.004462:0.004045:0.008735:0.005214:0.002688:0.005214:0.004556:0.009179:0.008198:0.008695:0.008735:0.003723:0.004556:0.008735:0.005214:0.004556:0.002688:0.008198:0.009045:0.004959:0.003723:0.008803:0.004045:0.003723:0.009165:0.009152:0.004462
tients previously on a NNRTI-based first-line :@0.082070:0.743919:0.358594:0.743919:0.358594:0.729890:0.082070:0.729890:0.004556:0.002688:0.008735:0.008198:0.004556:0.005214:0.003723:0.009165:0.004045:0.008735:0.007445:0.002688:0.008803:0.008171:0.005214:0.002688:0.007203:0.003723:0.008803:0.008198:0.003723:0.009179:0.003723:0.009945:0.009945:0.008158:0.005725:0.003037:0.004462:0.009165:0.009179:0.005214:0.008735:0.009206:0.003723:0.003272:0.003272:0.004045:0.005214:0.004556:0.004462:0.002688:0.002688:0.008198:0.008735:0.003723
regimen for whom DTG is unsuitable:@0.082070:0.756747:0.314688:0.756747:0.314688:0.742718:0.082070:0.742718:0.004045:0.008735:0.009045:0.002688:0.012606:0.008735:0.008198:0.003723:0.004220:0.008803:0.004045:0.003723:0.011168:0.008198:0.008803:0.012606:0.003723:0.009999:0.005725:0.011719:0.003723:0.002688:0.005214:0.003723:0.008171:0.008198:0.005214:0.008171:0.002688:0.004556:0.009179:0.009165:0.002688:0.008735
Failing on a NNRTI-based first-line regimen :@0.082070:0.772141:0.355543:0.772141:0.355543:0.758112:0.082070:0.758112:0.006518:0.009179:0.002688:0.002688:0.002688:0.008198:0.009045:0.003723:0.008803:0.008198:0.003723:0.009179:0.003723:0.009945:0.009945:0.008158:0.005725:0.003037:0.004462:0.009165:0.009179:0.005214:0.008735:0.009206:0.003723:0.003272:0.003272:0.004045:0.005214:0.004556:0.004462:0.002688:0.002688:0.008198:0.008735:0.003723:0.004045:0.008735:0.009045:0.002688:0.012606:0.008735:0.008198:0.003723
and DTG is suitable (drug-resistance testing :@0.082070:0.784969:0.364870:0.784969:0.364870:0.770940:0.082070:0.770940:0.009179:0.008198:0.009206:0.003723:0.009999:0.005725:0.011719:0.003723:0.002688:0.005214:0.003723:0.005214:0.008171:0.002688:0.004556:0.009179:0.009165:0.002688:0.008735:0.003723:0.004959:0.009206:0.004045:0.008171:0.009045:0.004462:0.004045:0.008735:0.005214:0.002688:0.005214:0.004556:0.009179:0.008198:0.008695:0.008735:0.003723:0.004556:0.008735:0.005214:0.004556:0.002688:0.008198:0.009045:0.003723
not necessary):@0.082070:0.797798:0.177528:0.797798:0.177528:0.783769:0.082070:0.783769:0.008198:0.008803:0.004556:0.003723:0.008198:0.008735:0.008695:0.008735:0.005214:0.005214:0.009179:0.004045:0.007203:0.004959
AZT+3TC+LpV/r:@0.382556:0.718262:0.478578:0.718262:0.478578:0.704233:0.382556:0.704233:0.009945:0.006451:0.005725:0.008144:0.007445:0.005725:0.010926:0.008144:0.006209:0.007956:0.009434:0.005873:0.004045
 :@0.382556:0.733656:0.386278:0.733656:0.386278:0.719627:0.382556:0.719627:0.003723
 :@0.382556:0.746485:0.386278:0.746485:0.386278:0.732456:0.382556:0.732456:0.003723
 :@0.382556:0.759313:0.386278:0.759313:0.386278:0.745284:0.382556:0.745284:0.003723
AZT+3TC+DTG:@0.382556:0.772141:0.472504:0.772141:0.472504:0.758112:0.382556:0.758112:0.009945:0.006451:0.005725:0.008144:0.007445:0.005725:0.010926:0.008144:0.009999:0.005725:0.011719
patients with anaemia and renal disease: switch :@0.596910:0.718262:0.913066:0.718262:0.913066:0.704233:0.596910:0.704233:0.007956:0.009179:0.004556:0.002688:0.008735:0.008198:0.004556:0.005214:0.003723:0.011168:0.002688:0.004556:0.008198:0.003723:0.009179:0.008198:0.009179:0.008735:0.012606:0.002688:0.009179:0.003723:0.009179:0.008198:0.009206:0.003723:0.004045:0.008735:0.008198:0.009179:0.002688:0.003723:0.009206:0.002688:0.005214:0.008735:0.009179:0.005214:0.008735:0.003723:0.003723:0.005214:0.011168:0.002688:0.004556:0.008695:0.008198:0.003723
to ABC.:@0.596910:0.731091:0.646299:0.731091:0.646299:0.717062:0.596910:0.717062:0.004556:0.008803:0.003723:0.009945:0.007714:0.010926:0.003723
Dyslipidaemia or intractable diarrhoea associ-:@0.596910:0.743919:0.895904:0.743919:0.895904:0.729890:0.596910:0.729890:0.009999:0.007203:0.005214:0.002688:0.002688:0.009165:0.002688:0.009206:0.009179:0.008735:0.012606:0.002688:0.009179:0.003723:0.008803:0.004045:0.003723:0.002688:0.008198:0.004556:0.004045:0.009179:0.008695:0.004556:0.009179:0.009165:0.002688:0.008735:0.003723:0.009206:0.002688:0.009179:0.004045:0.004045:0.008198:0.008803:0.008735:0.009179:0.003723:0.009179:0.005214:0.005214:0.008803:0.008695:0.002688:0.004462
ated with LpV/r: switch to ATV/r:@0.596910:0.756747:0.799949:0.756747:0.799949:0.742718:0.596910:0.742718:0.009179:0.004556:0.008735:0.009206:0.003723:0.011168:0.002688:0.004556:0.008198:0.003723:0.006209:0.007956:0.009434:0.005873:0.004045:0.003723:0.003723:0.005214:0.011168:0.002688:0.004556:0.008695:0.008198:0.003723:0.004556:0.008803:0.003723:0.009945:0.005725:0.009434:0.005873:0.004045
TDF should be added to second-line regimens if :@0.596910:0.769575:0.909800:0.769575:0.909800:0.755546:0.596910:0.755546:0.005725:0.009999:0.006518:0.003723:0.005214:0.008198:0.008803:0.008171:0.002688:0.009206:0.003723:0.009165:0.008735:0.003723:0.009179:0.009206:0.009206:0.008735:0.009206:0.003723:0.004556:0.008803:0.003723:0.005214:0.008735:0.008695:0.008803:0.008198:0.009206:0.004462:0.002688:0.002688:0.008198:0.008735:0.003723:0.004045:0.008735:0.009045:0.002688:0.012606:0.008735:0.008198:0.005214:0.003723:0.002688:0.004220:0.003723
hep B co-infection:@0.596910:0.782404:0.716908:0.782404:0.716908:0.768375:0.596910:0.768375:0.008198:0.008735:0.009165:0.003723:0.007714:0.003723:0.008695:0.008803:0.004462:0.002688:0.008198:0.004220:0.008735:0.008695:0.004556:0.002688:0.008803:0.008198
third-line therapy:@0.082070:0.813192:0.195227:0.813192:0.195227:0.798526:0.082070:0.798526:0.005644:0.008063:0.003225:0.004301:0.008870:0.005644:0.003225:0.003225:0.008063:0.008601:0.003763:0.004032:0.008063:0.008601:0.004301:0.008870:0.008870:0.007795
Failing any second-line regimen :@0.082070:0.828586:0.292218:0.828586:0.292218:0.814557:0.082070:0.814557:0.006518:0.009179:0.002688:0.002688:0.002688:0.008198:0.009045:0.003723:0.009179:0.008198:0.007203:0.003723:0.005214:0.008735:0.008695:0.008803:0.008198:0.009206:0.004462:0.002688:0.002688:0.008198:0.008735:0.003723:0.004045:0.008735:0.009045:0.002688:0.012606:0.008735:0.008198:0.003723
Individualised regimen rec-:@0.382556:0.828586:0.558340:0.828586:0.558340:0.814557:0.382556:0.814557:0.003037:0.008198:0.009206:0.002688:0.007445:0.002688:0.009206:0.008171:0.009179:0.002688:0.002688:0.005214:0.008735:0.009206:0.003723:0.004045:0.008735:0.009045:0.002688:0.012606:0.008735:0.008198:0.003723:0.004045:0.008735:0.008695:0.004462
ommended by the national :@0.382556:0.841414:0.566887:0.841414:0.566887:0.827385:0.382556:0.827385:0.008803:0.012606:0.012606:0.008735:0.008198:0.009206:0.008735:0.009206:0.003723:0.009165:0.007203:0.003723:0.004556:0.008198:0.008735:0.003723:0.008198:0.009179:0.004556:0.002688:0.008803:0.008198:0.009179:0.002688:0.003723
third-line committee, based on  advice. :@0.382556:0.854242:0.650304:0.854242:0.650304:0.840213:0.382556:0.840213:0.004556:0.008198:0.002688:0.004045:0.009206:0.004462:0.002688:0.002688:0.008198:0.008735:0.003723:0.008695:0.008803:0.012606:0.012606:0.002688:0.004556:0.004556:0.008735:0.008735:0.003723:0.003723:0.009165:0.009179:0.005214:0.008735:0.009206:0.003723:0.008803:0.008198:0.003723:0.009797:0.009179:0.009206:0.007445:0.002688:0.008695:0.008735:0.003723:0.003723
the patient’s genotype drug-:@0.382556:0.867070:0.571591:0.867070:0.571591:0.853041:0.382556:0.853041:0.004556:0.008198:0.008735:0.003723:0.009165:0.009179:0.004556:0.002688:0.008735:0.008198:0.004556:0.004717:0.005214:0.003723:0.009045:0.008735:0.008198:0.008803:0.004556:0.007203:0.009165:0.008735:0.003723:0.009206:0.004045:0.008171:0.009045:0.004462
resistance profile and Stanford :@0.382556:0.879899:0.584170:0.879899:0.584170:0.865870:0.382556:0.865870:0.004045:0.008735:0.005214:0.002688:0.005214:0.004556:0.009179:0.008198:0.008695:0.008735:0.003723:0.009165:0.004045:0.008803:0.003272:0.003272:0.002688:0.008735:0.003723:0.009179:0.008198:0.009206:0.003723:0.006693:0.004556:0.009179:0.008198:0.004220:0.008803:0.004045:0.009206:0.003723
score.:@0.382556:0.892727:0.421771:0.892727:0.421771:0.878698:0.382556:0.878698:0.005214:0.008695:0.008803:0.004045:0.008735:0.003723
Regimen includes DRV and :@0.382556:0.905555:0.563379:0.905555:0.563379:0.891526:0.382556:0.891526:0.008158:0.008735:0.009045:0.002688:0.012606:0.008735:0.008198:0.003723:0.002688:0.008198:0.008695:0.002688:0.008171:0.009206:0.008735:0.005214:0.003723:0.009999:0.008158:0.009434:0.003723:0.009179:0.008198:0.009206:0.003723
may include InsTIs and/or ETR.:@0.382556:0.918383:0.576832:0.918383:0.576832:0.904354:0.382556:0.904354:0.012606:0.009179:0.007203:0.003723:0.002688:0.008198:0.008695:0.002688:0.008171:0.009206:0.008735:0.003723:0.003037:0.008198:0.006693:0.005725:0.003037:0.005214:0.003723:0.009179:0.008198:0.009206:0.005873:0.008803:0.004045:0.003723:0.007203:0.005725:0.008158:0.003723
Requires supervised care. should be based :@0.596910:0.828586:0.880315:0.828586:0.880315:0.814557:0.596910:0.814557:0.008158:0.008735:0.009165:0.008171:0.002688:0.004045:0.008735:0.005214:0.003723:0.005214:0.008171:0.009165:0.008735:0.004045:0.007445:0.002688:0.005214:0.008735:0.009206:0.003723:0.008695:0.009179:0.004045:0.008735:0.003723:0.003723:0.006693:0.008198:0.008803:0.008171:0.002688:0.009206:0.003723:0.009165:0.008735:0.003723:0.009165:0.009179:0.005214:0.008735:0.009206:0.003723
on genotype resistance testing and on expert :@0.596910:0.841414:0.897933:0.841414:0.897933:0.827385:0.596910:0.827385:0.008803:0.008198:0.003723:0.009045:0.008735:0.008198:0.008803:0.004556:0.007203:0.009165:0.008735:0.003723:0.004045:0.008735:0.005214:0.002688:0.005214:0.004556:0.009179:0.008198:0.008695:0.008735:0.003723:0.004556:0.008735:0.005214:0.004556:0.002688:0.008198:0.009045:0.003723:0.009179:0.008198:0.009206:0.003723:0.008803:0.008198:0.003723:0.008735:0.006451:0.009165:0.008735:0.004045:0.004556:0.003723
TDF – tenofovir; 3TC – lamivudine; AZT – zidovudine; FTC – emtricitabine; ABC – abacavir; d4T – stavudine; EFV – efavirenz; NVp – nevirapine;  :@0.082070:0.932421:0.875784:0.932421:0.875784:0.920146:0.082070:0.920146:0.005009:0.008749:0.005703:0.003257:0.005880:0.003257:0.003986:0.007644:0.007173:0.007702:0.003692:0.007702:0.006515:0.002352:0.003540:0.003257:0.003257:0.006515:0.005009:0.009560:0.003257:0.005880:0.003257:0.002352:0.008032:0.011030:0.002352:0.006515:0.007150:0.008055:0.002352:0.007173:0.007644:0.003257:0.003257:0.008702:0.005644:0.005009:0.003257:0.005880:0.003257:0.004998:0.002352:0.008055:0.007702:0.006515:0.007150:0.008055:0.002352:0.007173:0.007644:0.003257:0.003257:0.005703:0.005009:0.009560:0.003257:0.005880:0.003257:0.007644:0.011030:0.003986:0.003540:0.002352:0.007608:0.002352:0.003986:0.008032:0.008020:0.002352:0.007173:0.007644:0.003257:0.003257:0.008702:0.006750:0.009560:0.003257:0.005880:0.003257:0.008032:0.008020:0.008032:0.007608:0.008032:0.006515:0.002352:0.003540:0.003257:0.003257:0.008055:0.006515:0.005009:0.003257:0.005880:0.003257:0.004563:0.003986:0.008032:0.006515:0.007150:0.008055:0.002352:0.007173:0.007644:0.003257:0.003257:0.006303:0.005703:0.008255:0.003257:0.005880:0.003257:0.007644:0.003692:0.008032:0.006515:0.002352:0.003540:0.007644:0.007173:0.004998:0.003257:0.003257:0.008702:0.008255:0.006961:0.003257:0.005880:0.003257:0.007173:0.007644:0.006515:0.002352:0.003540:0.008032:0.008020:0.002352:0.007173:0.007644:0.003257:0.003199:0.003257
ETR – etravirine; LpV/r – lopinavir/ritonavir; ATV – atazanavir; DRV – darunavir; InsTI – integrase strand transfer inhibitor, DTG – dolutegravir:@0.082070:0.943323:0.850043:0.943323:0.850043:0.931048:0.082070:0.931048:0.006303:0.005009:0.007138:0.003257:0.005880:0.003257:0.007644:0.003986:0.003540:0.008032:0.006515:0.002352:0.003540:0.002352:0.007173:0.007644:0.003257:0.003257:0.005433:0.006961:0.008255:0.005139:0.003540:0.003257:0.005880:0.003257:0.002352:0.007702:0.008020:0.002352:0.007173:0.008032:0.006515:0.002352:0.003540:0.005139:0.003540:0.002352:0.003986:0.007702:0.007173:0.008032:0.006515:0.002352:0.003540:0.003257:0.003257:0.008702:0.005009:0.008255:0.003257:0.005880:0.003257:0.008032:0.003986:0.008032:0.004998:0.008032:0.007173:0.008032:0.006515:0.002352:0.003540:0.003257:0.003257:0.008749:0.007138:0.008255:0.003257:0.005880:0.003257:0.008055:0.008032:0.003540:0.007150:0.007173:0.008032:0.006515:0.002352:0.003540:0.003257:0.003257:0.002658:0.007173:0.005856:0.005009:0.002658:0.003257:0.005880:0.003257:0.002352:0.007173:0.003986:0.007644:0.007914:0.003540:0.008032:0.004563:0.007644:0.003257:0.004563:0.003986:0.003540:0.008032:0.007173:0.008055:0.003257:0.003986:0.003540:0.008032:0.007173:0.004563:0.003692:0.007644:0.003540:0.003257:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.003257:0.003257:0.008749:0.005009:0.010254:0.003257:0.005880:0.003257:0.008055:0.007702:0.002352:0.007150:0.003986:0.007644:0.007914:0.003540:0.008032:0.006515:0.002352:0.003540